Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Stomach Neoplasms 2Advanced Solid Tumors 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma of the Stomach 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × tesetaxel × Clear all
NCT01573468 2012-07-24

TESEGAST

Genta Incorporated

Phase 2 Unknown
580 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01348009 2012-03-13

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Genta Incorporated

Phase 1/2 Unknown
63 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡